RAAS inhibition was also mentioned as a possible target for immunotherapy in several cancer types; in a matter of fact, AT1R provokes hypoxia in tumor cells, and increases inflammatory cytokines and reactive oxygen species; all of which can lead to an immunosuppressive environment.[27] Therefore, by using immunotherapy to target those pathways, we can improve therapy by improving medication distribution to the tissues and lowering required drug doses without compromising efficacy.[27]. Here, AGTR1 is linked to neoplasm.